Ergomed
Ergomed is a UK-based clinical research organization providing pharmacovigilance and clinical trial services to pharmaceutical and biotech sponsors through its PrimeVigilance and Ergomed Clinical Research divisions.
- Company typePublic
- Founded1997
- HeadquartersGuildford, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Ergomed does
Ergomed plc is a United Kingdom-based clinical research organization (CRO) founded in 1997 and headquartered in Guildford. The company provides specialized services to the pharmaceutical and biotech industries through two main divisions: PrimeVigilance, which delivers post-marketing pharmacovigilance and drug safety services including adverse event reporting, signal detection, and medical information management; and Ergomed Clinical Research, which provides full-service clinical trial management, site monitoring, and regulatory support.
The company's core technology is the PrimeVigilance platform, which incorporates AI/ML-driven workflows for real-time adverse drug reaction monitoring, EHR mining, and regulatory submission support (including FDA E2B(R3) compliance). Capabilities were expanded through the acquisition of Panacea Pharma Projects Limited. The company also operates wholly owned subsidiary PrimeVigilance as a core operating unit and has built a portfolio of acquired capabilities including MedSource, Ashfield Healthcare, PSR Group, and PharmInvent.
Ergomed generates revenue through B2B professional services contracts with pharmaceutical and biotech sponsors, including large pharmaceutical companies, mid-size biotechs, and emerging biotechs. Distribution occurs via direct enterprise sales, RFP processes, and contract negotiations, supplemented by industry conference participation. Historical revenue grew from approximately $90M in 2019 to $204M in 2023, supported by M&A activity and expansion of pharmacovigilance and clinical trial services.
Ergomed firmographics
Firmographics- Name
- Ergomed
- Legal name
- Ergomed plc
- Website
- https://ergomedplc.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Ergomed is a UK-based clinical research organization providing pharmacovigilance and clinical trial services to pharmaceutical and biotech sponsors through its PrimeVigilance and Ergomed Clinical Research divisions.
- Ownership category
- akta.pro rank
Ergomed industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Enterprise Risk Management (ERM) Advisory (BPAHAFAA)
Keywords
Where Ergomed is headquartered
LocationHeadquarters
- HQ city
- Guildford
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Ergomed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmacovigilance services: Ergomed generates revenue through providing post-marketing pharmacovigilance services to pharmaceutical and biotech companies. This includes adverse drug reaction monitoring, signal detection, and medical information services delivered via its PrimeVigilance division.
- Clinical trial support services: Ergomed provides clinical research organization (CRO) services including clinical trial management and operational support, as evidenced by its partnership with CEL-SCI to support trial preparations for Multikine. Services are delivered on a contract basis to pharmaceutical and biotech sponsors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Ergomed product offering
Product offeringCore offering
Ergomed is a clinical research organization (CRO) that provides specialized pharmacovigilance and clinical trial management services to pharmaceutical and biotech sponsors. Through its PrimeVigilance division it delivers post-marketing drug safety surveillance, adverse drug reaction monitoring, signal detection, and medical information services, while its Ergomed Clinical Research division provides full-service clinical trial management, site monitoring, biostatistics, data management, and regulatory support.
Product overview
Ergomed is a specialized pharmaceutical services company operating through two main divisions: PrimeVigilance (pharmacovigilance and drug safety services) and Ergomed Clinical Research (full-service clinical trial management). The PrimeVigilance unit was expanded through the acquisition of Panacea Pharma Projects Limited, while the clinical research division provides end-to-end trial services. The company serves pharmaceutical and biotech clients with a focus on drug safety monitoring and clinical development.
Differentiator
Problem solved
Functional benefit
Companies that use Ergomed
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Ergomed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Ergomed partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- OCT Europe 2026 (Arena International Events Group / GlobalData)minorErgomed Clinical Research participated as a presenter and exhibitor at the 16th Annual Outsourcing in Clinical Trials (OCT) Europe 2026 conference in Barcelona, Spain. The event brings together pharmaceutical and biotech industry leaders including GSK, Bayer, Sandoz, Alexion Pharmaceuticals, ICON, Parexel, Johnson & Johnson, and AstraZeneca. Ergomed's participation provides visibility and networking opportunities with potential pharmaceutical sponsors.
- CEL-SCI CorporationcoreErgomed partnered with CEL-SCI Corporation to support trial preparations for the Confirmatory Registration Study of Multikine, a cancer therapy. Ergomed provided clinical research organization services including trial management and operational support. CEL-SCI reported that Ergomed was engaged to support Multikine study preparations, with patient enrollment expected in Spring 2026.
- Panacea Pharma Projects LimitedcoreErgomed completed the acquisition of Panacea Pharma Projects Limited to expand its PrimeVigilance capabilities. The acquisition strengthens Ergomed's pharmacovigilance service offerings and broadens its ability to serve pharmaceutical sponsors with enhanced post-marketing surveillance and medical information services. Multiple market reports cite this acquisition as a key strategic development for Ergomed.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Ergomed competitors and assessment
Company assessmentBroad incumbents
- Thermo Fisher Scientific (PPD): Owns PPD, a leading global CRO offering clinical development and post-approval services including pharmacovigilance. Comparable as a broad incumbent in the same CRO market where Ergomed competes.
- IQVIA Holdings: World's largest CRO/contract commercial organization with deep clinical, real-world evidence, and safety/pharmacovigilance capabilities. Operates as a broad incumbent competing across Ergomed's full service portfolio at significantly greater scale.
- WuXi AppTec: Global CRO/CDMO with extensive clinical and safety services serving pharma/biotech, particularly strong in Asia-Pacific. Comparable to Ergomed in clinical operations and PV, and a key Asia-Pacific competitor.
- Labcorp Drug Development (formerly Covance): Major clinical CRO with global trial management and central laboratory capabilities, plus post-marketing safety services. Comparable to Ergomed across clinical operations, lab services, and pharmacovigilance.
Direct peers
- ICON plc: Global Tier-1 CRO providing full-service clinical trial management and pharmacovigilance services to pharma and biotech sponsors. Directly comparable to Ergomed across both clinical operations and PV service lines, and was a co-attendee at OCT Europe 2026.
- Syneos Health: Clinical and commercial solutions provider offering CRO services and pharmacovigilance. Comparable to Ergomed as a mid-to-large CRO serving pharma/biotech across the full clinical development lifecycle.
- Worldwide Clinical Trials: Mid-sized global CRO focused on clinical trial management across multiple therapeutic areas, with associated safety/pharmacovigilance offerings. Closely comparable in scale and service mix to Ergomed Clinical Research.
- Charles River Laboratories: Contract research organization with preclinical, clinical, and safety assessment capabilities including pharmacovigilance support. Comparable to Ergomed in serving pharma sponsors with combined safety and clinical services.
- Parexel International: Large CRO offering clinical development, pharmacovigilance, and regulatory services globally. Closely matches Ergomed's combined PV + clinical research model, and was a co-attendee at OCT Europe 2026 alongside Ergomed.
Emerging players
- Clinipace Worldwide: Mid-sized, therapeutically-focused CRO offering clinical trial management and related services to emerging biotech sponsors. Comparable in scale and mid-market sponsor focus to Ergomed Clinical Research.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Ergomed social profiles
Digital presenceErgomed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ergomed leadership team
Management profileNumber of profiles
Profiles7 records
Ergomed subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ergomed funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ergomed M&A and investment
M&A and investmentM&A8 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ergomed
What does Ergomed do?
Ergomed is a clinical research organization (CRO) that provides specialized pharmacovigilance and clinical trial management services to pharmaceutical and biotech sponsors. Through its PrimeVigilance division it delivers post-marketing drug safety surveillance, adverse drug reaction monitoring, signal detection, and medical information services, while its Ergomed Clinical Research division provides full-service clinical trial management, site monitoring, biostatistics, data management, and regulatory support.
Is Ergomed a public or private company?
Ergomed is a public company. It is classified as unknown and is currently operating.
When was Ergomed founded?
Ergomed was founded in 1997. It employs 1,001 to 5,000 people.
Where is Ergomed based?
Ergomed is headquartered in Guildford, United Kingdom, in the Europe region.
How does Ergomed make money?
Two revenue lines are on record. Pharmacovigilance services are the primary driver. The others are clinical trial support services.
Who are Ergomed's main competitors?
Broad incumbents on record are Thermo Fisher Scientific (PPD), IQVIA Holdings, WuXi AppTec and Labcorp Drug Development (formerly Covance). Direct peers are ICON plc, Syneos Health, Worldwide Clinical Trials, Charles River Laboratories and Parexel International. Clinipace Worldwide is listed as an emerging player.
Does Ergomed have an API?
No public API is recorded for Ergomed.
What industry is Ergomed in?
Ergomed's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 5417 and its SIC code is 8731.